Cost-effectiveness of treatment in adults with blood pressure of 130–139/80–89 mmHg and high cardiovascular risk in China: a modelling studyResearch in context

Cost-effectiveness of treatment in adults with blood pressure of 130–139/80–89 mmHg and high cardiovascular risk in China: a modelling studyResearch in context

Summary: Background: The most recent updated hypertension guidelines recommend individuals with systolic blood pressure (SBP)/diastolic blood pressure (DBP) of 130–139/80–89 mmHg and high cardiovascular risk should receive antihypertensive drug treatment. This study aimed to assess the benefits and...

Full description

Bibliographic Details
Main Authors:	Jiangtao Li, Dong Zhao, Jun Cai, Shuohua Chen, Shouling Wu, Yue Qi
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	The Lancet Regional Health. Western Pacific
Subjects:	Benefit Incremental cost-effectiveness ratios Cost-effectiveness Hypertension Cardiovascular disease
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666606523002808

Similar Items

Long-term effects of blood pressure 130–139/80–89 mmHg on all-cause and cardiovascular mortality among Chinese adults with different glucose metabolism
by: Chang-Sheng Sheng, et al.
Published: (2023-12-01)

Achievement rate of blood pressure <140/90 mmHg and <130/80 mmHg in subjects with hypertension; findings from a Japanese health checkup in 2017
by: Shinichiro Fujishima, et al.
Published: (2020-10-01)

Cost-effectiveness and budget impact analysis of screening and preventive interventions for cardiovascular disease in Myanmar: an economic modelling studyResearch in context
by: Zin Mar Win, et al.
Published: (2024-07-01)

Incremental net benefit of extending human papillomavirus vaccine to boys in oropharyngeal cancer burden: Meta-analysis of cost-effectiveness studies
by: Adikara Pagan Pratama, et al.
Published: (2024-10-01)

The impact of changing home blood pressure monitoring cutoff from 135/85 to 130/80 mmHg on hypertension phenotypes
by: Audes D.M. Feitosa, et al.
Published: (2021-07-01)

Universal Dental Adhesives: Cost-Effectiveness and Duration of Use
by: Ayman A. Banjar, et al.
Published: (2022-01-01)

130/80 mmHg as a unifying hypertension threshold for office brachial, office central, and ambulatory daytime brachial blood pressure
by: Shao‐Yuan Chuang, et al.
Published: (2023-03-01)

The cost of kidney dialysis in hospitals affiliated to Kurdistan University of Medical Sciences in 2016
by: Frdin Gharibi, et al.
Published: (2018-01-01)

Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer
by: Zhong J, et al.
Published: (2024-06-01)

Commentary: Beyond 10-year risk: A cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease
by: Aditya Shah, et al.
Published: (2022-07-01)

Cost‐Utility Analysis of Low‐Dose Pioglitazone in a Population With Prediabetes and a History of Stroke or Transient Ischemic Attack
by: Fei Yuan, et al.
Published: (2024-11-01)

A compare between myocardial topical negative pressure levels of -25 mmHg and -50 mmHg in a porcine model
by: Hlebowicz Joanna, et al.
Published: (2008-06-01)

How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality
by: Pierluigi Russo
Published: (2022-02-01)

Mayor beneficio con una meta de presión arterial sistólica menor de 130mmHg
by: Jose Alfie
Published: (2010-07-01)

Office blood pressure threshold of 130/80 mmHg better predicts uncontrolled out‐of‐office blood pressure in apparent treatment‐resistant hypertension
by: Chan Joo Lee, et al.
Published: (2021-03-01)

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
by: Michal Pochopien, et al.
Published: (2019-01-01)

Comparison of 15–20 mmHg versus 20–30 mmHg Compression Stockings in Reducing Occupational Oedema in Standing and Seated Healthy Individuals
by: Cleusa Ema Quilici Belczak, et al.
Published: (2018-01-01)

Cost-effectiveness analysis of the prevention of mother-to-child transmission of HIV
by: Shui-ling Qu, et al.
Published: (2022-06-01)

Quality-adjusted Life Years and Costs of Mechanical Thrombectomy for Very Elderly Patients with Acute Ischaemic Stroke
by: Takeshi INABA, et al.
Published: (2025-02-01)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
by: Xingyun Hou, et al.
Published: (2019-05-01)

Cost-effectiveness and feasibility of conditional economic incentives and motivational interviewing to improve HIV health outcomes of adolescents living with HIV in Anambra State, Nigeria
by: Obinna Ikechukwu Ekwunife, et al.
Published: (2021-07-01)

Pharmacoeconomic evaluation of treatments for Poly Cystic Ovarian Syndrome (PCOS)
by: Darakhshan Masroor, et al.
Published: (2024-09-01)

Prevalence Rates of Arterial Hypertension According to the Threshold Criteria of 140/90 or 130/80 mmHg and Associated Cardiometabolic and Renal Factors: SIMETAP-HTN Study
by: Vicente Pallarés-Carratalá, et al.
Published: (2023-10-01)

An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations
by: Hugo C. Turner, et al.
Published: (2021-08-01)

Cost-effectiveness of the Perioperative Pain Management Bundle a registry-based study
by: Suzana Bojic, et al.
Published: (2023-09-01)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines
by: Victor L. Mendoza, et al.
Published: (2021-12-01)

Cost-Effectiveness Analysis of Chemoradiation and Radiotherapy Treatment for Stage IIB and IIIB Cervical Cancer Patients
by: Puspitasari IM, et al.
Published: (2021-02-01)

Economics of Neuraminidase Inhibitor Stockpiling for Pandemic Influenza, Singapore
by: Vernon J. Lee, et al.
Published: (2006-01-01)

The use of cost-effectiveness analysis for health benefit package design – should countries follow a sectoral, incremental or hybrid approach?
by: Rob Baltussen, et al.
Published: (2023-10-01)

Economic Evaluation for Health Interventions: Narrative Review
by: Rasha A. Mosallam
Published: (2023-12-01)

Effectiveness of Diabetes Mellitus Type 2 Management in Prolanis Participants at the BPJS Kesehatan Sibolga
by: ester sitompul, et al.
Published: (2024-12-01)

Intensive care unit mortality and cost-effectiveness associated with intensivist staffing: a Japanese nationwide observational study
by: Saori Ikumi, et al.
Published: (2023-12-01)

Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
by: Jinsui Zhang, et al.
Published: (2023-09-01)

Clinical Effectiveness Evaluation and Cost-effectiveness Analysis of Comprehensive Geriatric Assessment and Multidisciplinary Team for Ambulatory Older Patients: A Cohort Study
by: Prakasit Virulhakul, et al.
Published: (2025-01-01)

Determinants of reverse dipping blood pressure in normotensive, non-diabetic population with an office measurement below 130/85mmHg
by: Ali Çoner, et al.
Published: (2021-10-01)

Cost-utility analysis of total knee arthroplasty alone and in comparison with post-surgical rehabilitation and conservative treatment in the Republic of Kazakhstan
by: Dinara Serikova-Esengeldina, et al.
Published: (2022-09-01)

Critical ICP Thresholds in Relation to Outcome: Is 22 mmHg the Answer?
by: Agnes Riparbelli, et al.
Published: (2023-01-01)

Intraocular pressure reduction in glaucoma: Does every mmHg count?
by: Hari Jayaram
Published: (2020-01-01)

Impact of Hyperuricemia on Incident Hypertension When Hypertension Definition Changes From 140/90 to 130/80 mmHg in a Large Taiwanese Population Follow‐Up Study
by: Yi‐Hsueh Liu, et al.
Published: (2025-02-01)

Economic evaluation of border closure for a generic severe pandemic threat using New Zealand Treasury methods
by: Matt Boyd, et al.
Published: (2018-10-01)